Hutchmed has dosed the first participant in a bridging study of tazemetostat to treat relapsed/refractory follicular lymphoma (R/R FL) in China.

The open-label, multicentre Phase II bridging study is designed to evaluate tazemetostat’s safety, pharmacokinetics, and efficacy to treat R/R FL patients.

The evaluation of tazemetostat’s efficacy in R/R FL patients who have mutations in EZH2 (Cohort 1) will be the study’s primary objective.

Some of the trial’s secondary objectives include assessing the therapy’s safety and the pharmacokinetics to treat R/R FL patients and efficacy to treat R/R FL patients who have EZH2 wild type (Cohort 2).

Dr Junning Cao of Shanghai Fudan University Cancer Center is the lead principal investigator of the study.

Developed by biotech company Epizyme, tazemetostat is a methyltransferase inhibitor of EZH2, which catalyses the methylation of histone H3 that controls the expression of various genes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In August last year, Hutchmed and Epizyme entered a strategic collaboration for the research, development, production and marketing of tazemetostat in China, Hong Kong, Macau and Taiwan.

Tazemetostat received the US Food and Drug Administration (FDA) approval to treat certain patients with advanced epithelioid sarcoma (ES) in January 2020 and certain R/R FL patients in June 2020.

Under the Clinically Urgently Needed Imported Drugs scheme, the Health Commission and Medical Products Administration of Hainan Province of China approved tazemetostat in May 2022 for use in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (Hainan Pilot Zone) to treat certain ES and FL patients consistent with the label as approved by the FDA.

Recently, Hutchmed dosed the first subject in the Phase I clinical trial of HMPL-A83 to treat advanced malignant neoplasm patients in China.